Jupiter Life Line Hospitals (JLHL) Q2 24/25 earnings summary

Executive summary

• Q2 FY25 income reached INR 324.2 crore, up 22.7% year-over-year; EBITDA grew 23.5% to INR 76.6 crore; PAT rose 52.9% to INR 51.5 crore, with a PAT margin of 15.9%.

• H1 FY25 revenue was INR 612.8 crore, up 20.5% YoY; EBITDA at INR 141.9 crore, up 22.3% YoY; PAT at INR 96.1 crore, up 9.6% YoY, with a PAT margin of 15.7%.

• Consolidated revenue from operations for Q2 FY25 was ₹3,225.78 million, up from ₹2,631.76 million in Q2 FY24.

• Expansion initiatives include 22 new beds in Pune, 75 beds being added in Indore (operational by Q4FY25), and Dombivli hospital construction progressing.

• Regulatory approvals for a second Pune unit are in advanced stages, with plans to increase total bed capacity to ~2,500.

Financial highlights

• Q2FY25 total income rose 22.7% YoY to Rs 324.2 crore; EBITDA up 23.5% to Rs 76.6 crore; PAT up 52.9% to Rs 51.5 crore.

• H1FY25 gross profit margin was 82.0%, and EBITDA margin was 23.2%.

• ARPOB for H1 was INR 57,700, up from INR 53,100 YoY; ALOS was 3.85 days; occupancy for H1 was 67.2%, up from 62.3% YoY.

• Basic EPS for H1FY25 was 15.60 (not annualized); Q2 EPS was ₹7.86.

• PAT for H1FY24 and Q2FY24 included deferred tax charge benefits, impacting YoY comparisons.

Outlook and guidance

• Indore hospital's 75 new beds expected to be operational by Q4FY25.

• Dombivli greenfield hospital construction underway for 500 beds, operations expected in 2026.

• Pune second hospital pending regulatory approvals, construction to begin after clearances, expected in next quarter.

• Plans underway to identify another location to increase total bed capacity to ~2,500.

• The company continues to focus on its core medical and healthcare services segment in India.